NASDAQ · SABS
SAB Biotherapeutics, Inc.
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
Loading market information…
NASDAQ · JSPR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Jasper Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Jasper Therapeutics, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jasper Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:01 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Feb 27, 2025 |
| -$1.62-27.56% vs estimate |
| $1.17M |
| Q3 2024 | Nov 7, 2024 | -$1.24-13.76% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $2.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$3.42-$0.06 (-1.72%)
Verrica Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.18% below the high.
$2.48-$0.02 (-0.8%)
Boundless Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.62% below the high.
$5.34$0.00 (0.0%)
Generation Bio Co.’s quoted price sits in the upper half of its reported 52-week range, 28.95% below the high.
$2.04$0.00 (0.0%)
Mural Oncology plc’s quoted price sits in the lower half of its reported 52-week range, 56.96% below the high.
$6.53+$0.19 (+2.92%)
NextCure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.55% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
